The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: A multicenter study

Pharmacotherapy

Volumn 31, Issue 8, 2011, Pages 767-775

  Yost, Raymond J ^a   Cappelletty, Diane M ^b   Bennett, Jill Hines ^c   Cat, Tram ^c   Dortch, Marcus ^c   Duong, Phu ^c   Geriak, Matthew ^c   Gooch, Mike ^c   Hansen, Amanda Colquitt ^c   Heinrich, Lynley ^c   Huynh, Nga ^c   Johnson, Sarah J ^c   Kernan, William ^c   Pasquale, Timothy R ^c   Patel, Gita Wasan ^c   Sarubbi, Christina ^c   Tart, Serina ^c  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c NONE

Author keywords

Extended infusion; Gram negative infection; Piperacillin tazobactam

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DORIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER INFECTION; ADULT; AGED; APACHE; ARTICLE; BACTEROIDES INFECTION; BLOODSTREAM INFECTION; CATHETER INFECTION; CITROBACTER INFECTION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXTENDED INFUSION; DRUG INFUSION; DRUG NONEXTENDED INFUSION; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; GRAM NEGATIVE INFECTION; HEALTH STATUS; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS CATHETER; KIDNEY FUNCTION; KLEBSIELLA INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PROTEUS INFECTION; PROVIDENCIA INFECTION; PSEUDOMONAS; PSEUDOMONAS INFECTION; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK REDUCTION; SERRATIA INFECTION; SKIN; SKIN INFECTION; STREPTOCOCCUS INFECTION; SURVIVAL TIME; TISSUE CULTURE; TREATMENT DURATION; UNITED STATES; URINARY TRACT; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79961104396     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.8.767     Document Type: Article

References (18)

1. Streit J, Jones R, Sader H, Fritsche T. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents 2004;24:111-18. (Pubitemid 38993688)
2. Lodise T Jr, Lomaestro B, Rodvold K, Danziger L, Drusano G. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-24. (Pubitemid 39577677)
3. Lodise T Jr, Lomaestro B, Drusano G. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63. (Pubitemid 46147617)
4. Roberts J, Boots R, Rickard C, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-91. (Pubitemid 47072068)
5. Benko A, Cappelletty D, Kruse J, Rybak M. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691-5. (Pubitemid 26071536)
6. Patel G, Patel N, Lat A, et al. Outcomes of extended-infusion piperacillin-tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis 2009;64:236-40.
7. Thalhammer F, Traunmüller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43:523-7. (Pubitemid 29182302)
8. Angus B, Smith M, Suputtamongkol Y, et al. Pharmacokinetic- pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000;49:445-52. (Erratum in Br J Clin Pharmacol 2000;50:184-91.)
9. Hanes S, Wood G, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-40.
10. McNabb J, Nightingale C, Quintiliani R, Nicolau D. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-55. (Pubitemid 32411052)
11. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002;54:1693-6. (Pubitemid 36018820)
12. Georges B, Conil J, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs an intermittent dosing regimen. Int J Clin Pharmacol Therapeut 2005;43:360-9. (Pubitemid 41078996)
13. Lau W, Mercer D, Itani K, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61. (Pubitemid 44684865)
14. Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219-23. (Pubitemid 43269850)
15. Rafati M, Rouini M, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7. (Pubitemid 44108605)
16. Adembri C, Ristori R, Chelazzi C, et al. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. J Thorac Cardiovasc Surg 2010;140:471-5.
17. Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. (Pubitemid 15250137)
18. Xamplas R, Itokazu G, Glowacki R, Grasso A, Caquelin C, Schwartz D. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital. Am J Health Syst Pharm 2010;67:622-8.